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Using a rat model, the effect of pre-treatment with FK 506 on hepatic ischemia/reperfusion injury was investigated. 
All control animals died within 72 h of the ischemia/reperfusion injury. Pre-treatment of the animals with FK 506 
(OJ mg/kg in 0.5 ml saline) administered intravenously improved survival. The most striking protection against fatal 
ischemia/reperfusion injury was achieved in rats that were given FK 506 6 and 24 h prior to the induction of the 
hepatic ischemic insult (70% and 80% 10-day survival rates, respectively). The hepatoprotective effect of FK 506 was 
assessed further in a second experiment in which the serum levels of tumor necrosis factor (TNF) and interleukin 6 
(IL-6) were measured. These results suggest that a 60-min period of hepatic ischemia and subsequent reperfusion 
triggers the release of both TNF and IL-6, and that FK 506 pre-treatment (6 h before the ischemic episode) significantly 
inhibits the production and/or release of these two cytokines compared to untreated controls. These data provide 
additional information concerning the immunosuppressive and hepatoprotective activities of FK 506. Based upon 
these data, it is probable that FK 506 attenuates hepatic ischemiajreperfusion injury, at least in part, by reducing 
TNF and IL-6 levels. 
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The success of organ transplantation. particularly liver 
transplantation (OLTx), as a treatment modality for end-
stage disease has created an increasing demand for donor 
organs that has outstripped the currently available donor 
supply. Compounding this problem is the observation 
that a number of donor livers either fail to function or 
function poorly in the immediate postoperative period 
(1,2). As a result. considerable research effort has been 
devoted to identifying means for preventing or diminish-
ing allograft injury resulting from organ harvesting, cold 
ischemia. reperfusion and rejection. FK 506. a potent 
immunosuppressive drug of the macrolide antibiotic 
class. has been shown to prevent or reverse both acute 
cellular and chronic allograft rejection in humans more 
reliably than has been possible heretofore (3). FK 506 
has also been shown to possess hepatotrophic activity 
(4,5). This latter effect is shared with cyclosporine A 
(CsA) (6-11). Both drugs are T-cell specific immuno-
suppressive agents that owe their immunosuppression 
activity to an inhibition of the synthesis and expression 
of interleukin 2 (IL-2) and possibly other cytokines 
(12,13). 
Tumor necrosis factor (TNF) and interleukin 6 (IL-6) 
are two cytokines recognized as critical early mediators 
of organ injury. One major source of TNF are 'activated' 
macrophages (14). The Kupffer cell mass within the liver 
is the largest fixed macrophage population of the body. 
Thus, the liver has a unique capacity for TNF pro-
duction. Previous studies using diverse models of hepato-
toxicity have suggested that TNF,js a terminal mediator 
of liver injury (15-17). Indeed. TNF has been suggested 
to play a role in models such as galactosamine liver 
injury (15), lead-enhanced endotoxic liver injury (16) and 
Propionibacterium acnes-induced liver injury (t 7). 
Furthermore. agents with block TNF production (e.g., 
prostaglandins and dexamethasone) and/or anti-TNF 
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antibodies have been shown to block or attenuate these 
models of liver injury (15,17). TNF is known to be 
involved in many inflammatory processes, and it can be 
detected during renal (18) and cardiac (19) allograft 
rejection. 
IL-6 is a glycoprotein which regulates growth and 
differentiation of both Band T lymphocytes, activates 
a spectrum of inflammatory cells and induces fever (20). 
Interleukin I (IL-I) and TNF trigger endothelial cells 
(22) and hepatocytes (23) to release IL-6. 
The purpose of the present investigation was to exam-
ine the effect of FK 506 in (a) ameliorating the hepatic 
injury associated with warm ischemialreperfusion in rats 
subjected to a 70% hep.ltectomy and (b) to determine 
whether the immunosuppressive and hepatotrophic qual-
ities of FK 506 are due, at least in part, to inhibition of 
the production and/or release of TNF and IL-6. 
Materials and Methods 
Animal model 
By utilizing a rat model of lobar, rather than total 
hepatic ischemia, a severe ischemic insult can be pro-
duced without also inducing mesenteric venous hyper-
tension (24). Utilizing an atraumatic microvascular 
clamp to interrupt the portal venous and hepatic arterial 
blood supply to the right lateral lobe of the liver, a 60-
min period of total ischemia was produced. With this 
procedure. the median and left lateral lobes of the liver 
retain an intact blood flow. Intestinal venous congestion 
and the possible leakage of bacteria or bacterial products 
into the circulation is minimized (25,26). Upon releasing 
the clamp and reperfusion of the right lateral lobe, the 
median and left lateral lobes of the liver were excised. 
leaving behind only the previously ischemic right hepatic 
lobe. All animals used in these studies were adult male 
Lewis rats (Harlan-Sprague-Dawley, Indianapolis, IN) 
weighing 200-300 g which were given free access to 
standard pellet diet and tap water both before and after 
the operative procedure. Anesthesia was induced and 
maintained using metofane inhalation. 
Experimental protocols 
Experiment J. Rats, prepared as described above, were 
assigned to one of six different experimental groups 
consisting of J 0 rats each. Group 1 animals were injected 
intravenously with 0.5 ml saline solution and served as 
the controls. Animals in groups 2-6 were injected intra-
venously with FK 506 (0.3 mg/kg in 0.5 ml saline) 
(Fujiaawa Corporation. Philadelphia. PAl at 0, 1. 3, 6 
o~IKO4 h prior to the production of the experimental 
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hepatic ischemia. All animals were allowed to recover 
spontaneously and survival was determined at 12-h 
intervals for a total of 10 days. 
Experiment 2. An additional 1 \0 rats. consisting of 
five rats in each group prepared identically to those in 
groups I and 5 in Exp. 1, were sacrificed at 24-h intervals 
beginning immediately after removal of the microvascu-
lar clamp at time zero and continuing for the next 10 
days. Immediately before being killed. blood was 
obtained from the intrahepatic inferior vena cava (lVC) 
of each animal for bioassay of circulating TNF and IL-
6 concentrations. In addition, blood samples (0.75 ml) 
were obtained immediately before the 60-min period of 
ischemia (Le., I h before the time of reperfusion; -I h) 
to determine the pre-ischemic serum concentration of 
TNF and IL-6. At each blood draw. the blood withdrawn 
from each animal was replaced by an equal volume of 
lactated Ringer's solution. The serum was separated 
immediately and stored at - 20°C until being assayed. 
TNF bioassay 
The measurement of TNF utilized was based upon 
quantitation of the cytolytic activity of TNF in lysing 
L-M (murine mouse connective tissue) cells in the pres-
ence of actinomycin D as measured by the uptake of 
Crystal violet dye by residual viable cells (Genentech 
Inc, San Francisco, CAl (27). Briefly, L-M cells were 
cultivated in serum-free medium (M 199 containing 0.5% 
Bactopeptone). Confluent monolayers were detached 
using sterile glass beads. resuspended in M 199 supple-
mented with 0.5% Bactopeptone. 100 U Iml penicillin. 
100 Ilglml streptomycin. I Ilg/ml insulin and 0.024 M 
Hepes buffer. The cells were then seeded at a density of 
4·1<r cells per well into a 96-well microtiter plate. 
Following incubation for 22-24 h at 37°C in a humidi-
fied atmosphere with 5% CO2, the medium in the wells 
was replaced with fresh medium containing actinomycin 
D at a final concentration of 1 Ilg/m!. The plates are 
then incubated for an additional 18-20 h at 37 °C and 
stained with 0.5% Crystal violet, washed. dried and read 
by a plate reader at 540 nm. Activity levels are reported 
as units/mi. where 1 U/ml equals approx. 8.8 pg TNFI 
mL 
I L-6 bioassay 
The levels of IL-6 in serum were measured utilizing a 
bioassay system consisting of a hybridoma cell line B9, 
which was developed in the laboratory of Dr. L.A. 
Aarden (28). This cell line requires IL-6 for its prolifera-
tion and survival in vitro. The cells are maintained in 
medium consisting of RPMI-l640 containing 10% heat-
inactivated fetal calf serum (HI-FCS), 200 IlM glutamine. 
FK 506 PRE-TREATMENT REDUCES TNF AND IL-6 
5- 10- 5 M 2ME (mercaptoethanol). and 20-50 units/ml 
of HGF (hybridoma growth factor). One unit/ml of 
HGF is the concentration of IL-6 required to achieve 
50% maximal [3H]thymidine incorporation (28.29). 
The assay (30.31) is carried out as follows: 89 hybri-
doma cells are washed three times using sterile RPMI-
1640 containing 1% HI-FCS. The cells are then resus-
pended in double strength media (2' RPM 1-1640 con-
taining 20% HI-FCS) at a concentration of 2' I <r/ml. 
One hundred-Ill aliquots of the cell suspension were 
plated into individual wells of a 96-well microtiter plate. 
One hundred III of a 2-fold scri,,1 dilution of the serum 
to be assayed. diluted in RPMI-1640 containing 1% HI-
FCS was added to each of the wells. The plates were 
then incubated for 84 h at 37 nc in a humidified atmo-
sphcre with 5';;, CO 2 and pulscd with 0.5 IlCi of 
[JH]thymidine that is incorporated and determined by 
liquid scintillation counting. The amount of IL-6 (in 
HGF units) in the serum sample is defined as the 
reciprocal of the dilution required to produce 50% 
maximum CH]thymidine incorporation by the 89 cell 
line where I HGF unit equals I pg/ml or 5· 10- 14 M 
native IL-6. 
In order to determine whether FK 506 itself influenced 
either the TNF or IL-6 bioassay, serum and plasma 
samples taken from rats treated with varying concen-
trations of FK 506 were utilized in both bioassays. 
Samples taken from FK 506-treated rats had no detecta-
ble effect on either bioassay. Serum and plasma samples 
were also spiked with TNF (400 units per ml recombi-
nant human TNF) or IL-6 (12.5 or 25 units per ml 
recombinant human IL-6). Recovery in all samples was 
greater than 90%. Thus, FK 506 did not interfere with 
either bioassay and did not stimulate inhibitors of either 
TNF or IL-6. 
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Statistical analysis 
Values are expressed as the mean ± the standard 
error of mean. Differences in the means were tested after 
conversion of the primary data to logarithms using the 
Student t-test. Differences in proportions were evaluated 
using the Fisher Exact Test: one-tailed significance levels 
were used for the survival data analysis because the null 
and alternative hypotheses tested specified the direction 
of the difference (i.e., proportion of treated animals 
surviving would be greater than proportion of control 
animals surviving). A p-value of < 0.05 was considered 
to be statistically significant. 
Results 
Survival rate 
The IO-day survival rate for each of the six groups of 
animals studied is shown in Fig. I. All of the group I 
controls died within 72 h of the ischemic episode. The 
survival in animals receiving FK 506 (0.3 mg/kg) at 
time 0 (group 2), I h (group 3), and 3 h (group 4) before 
the induction of ischemia was increased slightly to 30%, 
40%, and 40%, respectively. In contrast. the survival for 
the group 5 and 6 animals that received the same dose 
of FK 506 but administered 6 h (group 5) and 24 h 
(group 6) before the initiation of the hepatic ischemia 
was increased significantly (p<O.OI) to 70% and 80%. 
respectively. As may be seen also in Fig. I, the survival 
rate remained constant from day 3 post-ischemia 
through 10 days in all groups of animals studied. Fig. 2 
shows a significant positive correlation between the time 
of FK 506 injection and the percentage of animals 
surviving at 72 h after the hepatic ischemia (r=0.854, 
p<0.05). 
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Fig. 2. Serum TNF levels IU/mll in groups I and 5. The points 
represent the mean level and the brackets indicate the standard error 
of the mean ,·groups significantly different at p < 0.001: "groups 
slgnilicantly different at p<O.O\l. No data are shown for the controls 
beyond 4X h because all of the animals had died. 
TN F levels/allowing hepatic isc:hemia;reperjusion 
TNF was measurable in the serum of all experimental 
animals after hepatic ischemia and reperfusion. In con-
trast. TNF was undetectable in the pre-ischemic samples 
obtained from the animals in both groups I and 5. The 
mean peak TNF level in the group I controls was 7.2 UI 
ml with a range of 6.47-8.53 U/ml and occurred at 24 h 
post-ischemia. The mean peak TNF level was 2.99 UI 
ml with a range of 2.81-3.06 U Iml in group 5 animals 
that received FK 506 6 h before the induction of ischemia 
and occurred at 48 h after the ischemic episode (Fig. 3). 
At each time interval studied. the mean value of TNF 
was significantly lower in the rats receiving FK 506 
(group 5) than it was in the controls (p < 0.0 I). 
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FiR.3. Serum IL-6 levels (pg/mll in groups I and S. The points 
represent the mean level and the brackets indicate the standard error 
of the mean ,·groups significantly different at p<O.02S). No data are 
shown for the control anImals beyond 48 h as all anamals in this group 
had died. 
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The serum IL-6 level in both groups of animals 
(groups 1 and 5) increased after the ischemia/reperfusion 
and peaked at 24 h. Statistically significant differences 
were found for the levels in both groups at 24 hand 
48 h post-ischemia (Fig. 4). The production of IL-6 
returned to the pre-ischemic values « I pg/ml) by 10 
days post~ischemiaK 
Discussion 
In the present experimental model. when control rats 
were subjected to a 70% hepatectomy involving the 
median and left lateral lobes of the liver after having 
sustained a 60-min period of total ischemia of the 
unresected right hepatic lobe. they all died within 72 h 
(Fig. 1). Survival of such animals is dependent upon the 
ability of the residual right hepatic lobe to withstand 
the initial ischemia and subsequent reperfusion injury 
and to regenerate. Pre-treatment of the animals with a 
single dose of FK 506 (0.3 mg/kg) administered intra-
venously 6 to 24 h prior to the induction of the hepatic 
ischemia (groups 5 and 6. respectively) was followed by 
a significant improvement in animal survival (70% and 
80%. respectively) (Fig. 1). 
It is well known that CsA augments hepatic regenera-
tion in rats (7 -\ 0) and mice (II) after partial hepatectomy 
and also in dogs with an Eck-fistula (6). In both models. 
the effect of an infusion of FK 506 at a much lower 
dose is similar (4.5). Thus. the recent observation that 
the events of hepatic regeneration may be modulated 
immunologically is of considerable interest (32-34). An 
ischemic injury may be followed by an increased expres-
sion of antigens by the injured organ which can initiate 
an immunologic response that leads to an inflammatory 
reaction which brings to the injured organ cells that 
further enhance the liver cell injury. In turn. the immune 
response becomes more intense (35). Since both CsA and 
FK 506 are immunosuppressive as well as hepatotrophic. 
it has been suggested that they might reduce the immune 
response to the injured graft as well as modulate hepato-
cyte growth and thereby enhance regeneration (5.36) . 
However. it is equally possible that the hepatoprotec-
tive effect of FK 506 herein observed is independent 
of its immunosuppressive action (4). The non-immuno-
logic actions of FK 506 appear to be attributed to its 
interaction with the enzyme ('is-trulls peptidyl-
prolylisomerase (PPlase), a principal constituent of the 
cytosolic binding sites of esA. cyclophilin (37.38) as well 
as FK 506 binding within cells (39.40). A biochemical 
mechanism for the beneficial hepatoprotective effect of 
l 
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FK 506 is supported by the demonstration. in a similar 
model. of a faster and more complete restoration of 
hepatic ATP content. and a reduction in the hepatic 
necrosis and cytosolic enzyme loss experienced following 
ischemia/reperfusion (4\). Thus. enhanced resistance to 
hepatic ischemic injury may contribute to the increased 
survival reported for the FK 506 pretreated animals. 
The present data show that a 60-min period of lobar 
hepatic ischemia followed by reperfusion and 70% hepa-
tectomy (involving the non-ischemic lobes) results in 
TNF production (Fig. 3). This finding is consistent with 
reports from other investigators (42.43). The mechanism 
of induction of TNF bioactivity seen after hepatic 
ischemia/reperfusion is not completely olear. however. It 
appears most likely that the process of ischemia;reperfu-
sion causes immunologically non-specific activation of 
hcpatic macro phages (Kupffcr cells) resulting in a release 
of this cytokine into thc systemic circulation. Previous 
studies in vitro have documented the ability of Kupffer 
cells to produce TNF (44). Unlike recent reports of a 
rapid increase in TNF following hepatic infection with 
murine virus. in the present study the increase in TNF 
was delayed 24-36 h (45). This apparent delay until the 
peak of TNF was noted probably reflects the time 
required for macrophage activation following ischemia/ 
reperfusion. Previous studies reported an immediate 
increase in TNF following viral infection involved pre-
treatment of the animals for 7 days prior to the injury 
induced to guarantee an acceleration of activated macro-
phages within the liver as the source of the TNF (45). 
Previous studies have reported that TNF not only 
has a deleterious effect on hepatocytes but also has 
damaging pulmonary effects resulting in pulmonary 
neutrophil sequestration and hemorrhagic edema (42,43). 
This observation may be of clinical importance especially 
in the field of transplantation as primary non-function 
of the graft is associated frequently with the rapid 
development of pulmonary insufficiency (46). 
The mechanisms by which TNF produces pulmonary 
and hepatic as well as other organ injury have not yet 
been clarified. However. TNF has been demonstrated to 
induce the expression of endothelial cell adherence pro-
teins which are responsible for binding neutrophils and 
monocytes (47,48). TNF also has been shown to activate 
neutrophils. increase phagocytic activity and cause their 
degranulation. as well as acting as a chemoattractant 
(45.50). It causes neutrophils to produce superoxide 
anions. hydrogen peroxide and other toxic metabolites 
(48.51). It also induces endothelial cells to produce a 
variety of cytokines (52-56). Thus, the vascular injury 
that follows hepatic ischemia/reperfusion may occur as 
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a consequence of the action of TNF on endothelial cells 
and neutrophils. Alternatively, it is possible that the high 
levels of plasma IL-6 reflect the severity of the biological 
mechanisms involved in rescuing the injured liver. This 
latter hypothesis is unlikely, however. as the utilization 
of monoclonal antibodies to IL-6 does not impair regen-
eration but does reduce tissue injury following a variety 
of tissue insults (15-17). 
In the present experiments (Exp. 2). a single intrave-
nous dose of FK 506 (0.3 mg/kg) administered 6 h prior 
to the induction of ischemia significantly inhibited TNF 
production (Fig. 3). While the precise mode of inhibition 
of TNF activity by FK 506 remains unknown. one 
explanation may be that FK 506 has a direct effect on 
macrophages or on the communication between macro-
phages and T lymphocytes. Since both cells are required 
for T-cell activation (lL-2 production). the identity of 
the particular cell lines affected by FK 506 is an impor-
tant issue that merits further evaluation. 
In the present study, lobar hepatic ischemia/reperfu-
sion injury resulted in the production of IL·6 with IL·6 
levels peaking at 24 h post-ischemia. Significant inhibi-
tion of IL-6 production occurred following the admin-
istration of FK 506 (group 5) (Fig. 4). Moreover, the use 
of FK 506 6 to 24 h prior to the hepatic ischemia 
dramatically improved survival. 
IL-6 is produced by a wide variety of cells including 
monocytes/macrophages, endothelial cells as well as T 
and B lymphocytes. Inducers of IL-6 production include 
IL-I and TNF, suggesting that the effect of IL-I and 
TNF as part of the acute phase response could be 
mediated, at least in part, by IL·6 (56). Because IL-6 
has a broad spectrum of target cells. it influences a 
broad array of immune and inflammatory responses in 
vitro and possibly also in vivo (20). 
The stimulation ofT-cell proliferation by IL-6 involves 
not only a direct growth-promoting signal, but also the 
induction of IL-2 receptors. This latter event converts 
T-cells to an IL-2-responsive state (20). B-cell growth 
and differentiation to antibody-secreting cells is 
enhanced by IL-6 in the presence of the appropriate 
stimuli (58,59). The hepatocyte is yet another major 
target of IL-6 (57). IL-6 exhibits a synergistic effect with 
IL-J on the induction of acute-phase protein production 
by hepatocytes. An inhibition of IL-6 release by FK 506 
pre-treatment may be one of the mechanisms behind the 
observed hepatoprotective action of FK 506. 
In conclusion, our data showed that FK 506 pre-
treatment attenuates the hepatic injury resulting from 
ischemia/reperfusion manifested as an improvement in 
survival. Hepatic ischemiaireperfusion injury triggers the 
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release ofTNF and IL-6. FK 506 inhibits the production/ 
release of these two cytokines. These findings contribute 
to an understanding of the full spectrum of immuno-
suppressive and hepatoprotective effects of FK 506. 
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